Scientists hunt for early warning signs in Tough-to-Treat leukemia
NCT ID NCT02827617
First seen Nov 18, 2025 · Last updated May 14, 2026 · Updated 24 times
Summary
This study aimed to find biological markers that could predict early on whether the drug ibrutinib would work in people with a high-risk form of chronic lymphocytic leukemia (CLL) that has a TP53 mutation. Researchers followed 56 patients who were already planning to take ibrutinib, collecting blood samples to look for genetic changes. The goal was to see if clearing the mutated cells or detecting resistance in blood DNA could help doctors decide sooner if treatment is working.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Clinica Ematologica, Centro Trapianti e Terapie Cellulari "Carlo Melzi"
Udine, 33100, Italy
-
Clinica Luganese Moncucco
Lugano, 6903, Switzerland
-
Department of Haematology, Tor Vergata Hospital
Rome, 00133, Italy
-
Department of Medical and Surgical Sciences, section of Hematology
Modena, 41124, Italy
-
Dipartimento di Ematologia, Niguarda Cancer Center, Ospedale Niguarda
Milan, 20133, Italy
-
Division of Hematology, Department of Internal Medicine, Basel University Hospital
Basel, 4031, Switzerland
-
Divisione di Ematologia, Universita' del Piemonte Orientale
Novara, 28100, Italy
-
Ematologia, Ospedale di Circolo e Fondazione Macchi
Varese, 21100, Italy
-
Hematology, Luzern Kantonsspital
Lucerne, 6000, Switzerland
-
Institute of Hematology, Catholic University S. Cuore
Roma, 00168, Italy
-
Onco Ematologia Clinico Sperimentale, I.R.C.C.S. Centro di Riferimento Oncologico
Aviano, 33081, Italy
-
Oncology Institute of Southern Switzerland
Bellinzona, Switzerland, 6500, Switzerland
-
Ospedale San Raffaele
Milan, 20132, Italy
Conditions
Explore the condition pages connected to this study.